The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience†
Bioulac‐Sage, P., Laumonier, H., Couchy, G., Le Bail, B., Sa Cunha, A., Rullier, A., Laurent, C., Blanc, J., Cubel, G., Trillaud, H., et al. (2009) · Hepatology · doi:10.1002/hep.22995 · Cited by 439
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
Zhang, W., Konopleva, M., Shi, Y.-X., McQueen, T., Harris, D., Ling, X., Estrov, Z., Quintás-Cardama, A., Small, D., Cortes, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm328 · Cited by 338
Sorafenib in Advanced Hepatocellular Carcinoma
Harnois, D. M. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79537-9 · Cited by 257
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Perifosine: Update on a novel Akt inhibitor
Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221
Barnett, S., Bilodeau, M. T., & Lindsley, C. W. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507714 · Cited by 146
Lindsley, C. W. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790980602 · Cited by 127
Chen, K., Yeh, P.-Y., Yeh, K., Lu, Y., Huang, S., & Cheng, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0257 · Cited by 123
Self-citationVitale, A., Volk, M. L., Pastorelli, D., Lonardi, S., Farinati, F., Burra, P., Angeli, P., & Cillo, U. (2009) · Hepatology · doi:10.1002/hep.23260 · Cited by 105
Molecular targeted therapy for hepatocellular carcinoma
Thomas, M. B. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-008-2252-z · Cited by 94
Chen, K., Yeh, P.-Y., Hsu, C., Hsu, C., Lu, Y., Hsieh, H., Chen, P., & Cheng, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806268200 · Cited by 87
Self-citationLindsley, C. W., Barnett, S. F., Layton, M. E., et al. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783497096 · Cited by 87
Sorafenib in advanced hepatocellular carcinoma.
Palmer, D. H. (2008) · PubMed · Cited by 87
Chen, K., Yu, H., Liu, T., Lee, S., Chen, P., & Cheng, A. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.011 · Cited by 76
Self-citationSorafenib in advanced hepatocellular carcinoma.
Copur, M. S. (2008) · PubMed · Cited by 74
HCC Heterogeneity: Molecular Pathogenesis and Clinical Implications
Fransvea, E., Paradiso, A., Antonaci, S., & Giannelli, G. (2009) · Analytical Cellular Pathology · doi:10.1155/2009/134921 · Cited by 53
Hcc Surveillance: Who Is the Target Population?
Bruix, J., & Llovet, J. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50142 · Cited by 52
Molecular targets for liver cancer therapy: From screening of target genes to clinical trials
Midorikawa, Y., Sugiyama, Y., & Aburatani, H. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00583.x · Cited by 20
Tyrosine kinase inhibitors to treat liver cancer
Huynh, H. T. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903571659 · Cited by 20
Sorafenib for liver cancer: the horizon broadens
Johnson, P. J., & Billingham, L. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70317-6 · Cited by 16
Scanga, A. E., Kowdley, K. V., Kowdley, K. V., McCaughan, G. W., & Trautwein, C. (2008) · Hepatology · doi:10.1002/hep.22756 · Cited by 11
Comparison of Staging Systems for HCC: One More Positive Answer or Mission Impossible? *
Huo, T., Wu, J., & Lee, S. (2005) · Hepatology · doi:10.1002/hep.20758 · Cited by 7
Cited by
Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M., Shia, J., Hechtman, J. F., Kundra, R., El Dika, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2293 · Cited by 602
Xia, H., Ooi, L. L. P. J., & Hui, K. M. (2013) · Hepatology · doi:10.1002/hep.26369 · Cited by 378
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Zhai, B., Hu, F., Jiang, X., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1043 · Cited by 284
Metadata
- Authors
- Chen, K.-F., Chen, H.-L., Tai, W.-T., Feng, W.-C., Hsu, C.-H., Chen, P.-J., & Cheng, A.-L.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 337
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2063488708
- Cited by
- 317
- References
- 32
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.